09:27 AM EDT, 06/25/2024 (MT Newswires) -- AbbVie ( ABBV ) said Tuesday that it has received a complete response letter from the US Food and Drug Administration for the New Drug Application for ABBV-951, to treat motor fluctuations in people with advanced Parkinson's disease.
The drugmaker said that the regulator cited issues from an inspection of a third-party manufacturer, and that the facility did not involve ABBV-951.
AbbVie ( ABBV ) said it is working with the FDA to address these observations and bring the therapy to patients.
AbbVie ( ABBV ) said there were no safety, efficacy, or labeling issues related to the drug were identified.
Price: 172.25, Change: -0.49, Percent Change: -0.28